# Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

> **NCT00898287** · PHASE1,PHASE2 · COMPLETED · sponsor: **Piramal Enterprises Limited** · enrollment: 23 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** P276-00
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00898287
- **Lead sponsor:** Piramal Enterprises Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00898287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00898287, "Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00898287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*